However, LY96 was downregulated in breast cancer, and LY96 suppression can inhibit cancer development both in vivo and in vitro (Zhang et al., 2017; Zheng et al., 2021), which was inconsistent with our result. This evidence concerns the gene LY96 and breast cancer.